Table 11.
CsA C0 compliances within the therapeutic range in patients with IFTA (1–5 years and >5 years post-transplantation groups).
| Number of Subjects with IFTA | 1–5 Years (CsA + MMF) |
1–5 Years (CsA) |
>5 Years (CsA + MMF) |
>5 Years (CsA) |
Total | |
|---|---|---|---|---|---|---|
| 10 (19.6%) Out of 51 |
1 (33.33%) Out of 3 |
20 (20.8%) Out of 96 |
8 (17.4%) Out of 46 |
39 (19.9%) Out of 196 |
||
| Therapeutic range | < 75 µg/L | 1 (10.0%) |
- | 5 (25.0%) |
2 (25.0%) |
8 (20.5%) |
| 75–150 µg/L | 7 (70.0%) |
1 (100.0%) |
13 (65.0%) |
5 (62.5%) |
26 (66.7%) |
|
| > 150 µg/L | 2 (20.0%) |
- | 2 (10.0%) |
1 (12.5%) |
5 (12.8%) |
IFTA—interstitial fibrosis and tubular atrophy; CsA—cyclosporine; MMF—mycophenolate mofetil.